
WVE Stock Forecast & Price Target
WVE Analyst Ratings
Bulls say
Wave Life Sciences is supported by a differentiated PRISM platform that spans RNA editing, antisense silencing, and RNA interference, giving it multiple shots on goal across rare and prevalent diseases rather than relying on a single asset. The clearest fundamental driver is WVE-006, where FDA alignment on a single two-year registrational trial with a one-year biomarker interim and use of the company’s LC-MS assay reduces regulatory friction, while clinical biomarker data already show meaningful AAT restoration and Z-AAT reduction. Wave also has a strong balance of platform validation and financial runway, with GSK-selecting a SpiNA candidate triggering a $12M milestone and about $431.0M in cash and investments supporting operations into 3Q28, alongside WVE-007, WVE-008, and other programs that expand long-term upside.
Bears say
Wave Life Sciences is facing substantial clinical and regulatory uncertainty, as efficacy and safety updates from its programs may fail to meet the approval bar and regulators could impose additional requirements or disagree with management’s interpretation of the FDA genome-editing long-term follow-up guidance. Competitive timing also looks unfavorable, with BEAM-302 potentially reaching U.S. AA ahead of WVE-006, while the lack of disclosed trial size, interim cut, or endpoints leaves the development timeline vulnerable to delay. Even if clinical data are positive, commercialization remains risky because competing RNA-silencing platforms could pressure market share and the company may need additional financing, raising dilution risk before profitability.
This aggregate rating is based on analysts' research of Wave Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
WVE Analyst Forecast & Price Prediction
Start investing in WVE
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Wave Life Sciences Inc (WVE) Forecast
WVE Analyst Forecast & Price Prediction
Start investing in WVE
Order type
Buy in
Order amount
Est. shares
0 shares